首页 > 最新文献

Gastroenterologia y hepatologia最新文献

英文 中文
Exploring infliximab serum level variability in inflammatory bowel disease: Comprehensive analysis of patient subgroups and treatment outcomes 探讨炎症性肠病中英夫利昔单抗血清水平变异性:对患者亚组和治疗结果的综合分析“炎症性肠病中英夫利昔单抗水平变异性”。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-12-01 Epub Date: 2025-05-23 DOI: 10.1016/j.gastrohep.2025.502472
Carles Iniesta-Navalón , Lorena Rentero-Redondo , Rosa Gómez-Espín , Manuel Ríos Saorín , Isabel Nicolás de Prado , Juan José Gascón-Cánovas

Background and aims

Inflammatory bowel disease (IBD) features diverse clinical presentations and progressions, impacting IFX exposure. Understanding IFX serum concentration changes is crucial for tailored monitoring in specific patient groups. The main objective of this study was to analyze ITL trajectories in patients with IBD to identify distinct groups and subgroups, revealing heterogeneity in treatment responses.

Methods

A retrospective cohort study was conducted involving IBD patients treated with infliximab in a regional reference hospital in Spain. Latent class linear mixed models were applied to identify subgroups based on serum infliximab measurements over time. To analyze the factors associated with IFX discontinuation, we employed both logistic regression and Cox regression models.

Results

The study included 165 IBD patients, and a total of 799 ITL samples were analyzed. The selected model included three clusters, with a random intercept and a random effect on both time and natural cubic spline time in the linear mixed model. Cluster 1 (20.6%) had lower IFX exposure, with 93.9% experiencing treatment discontinuation, compared to 45.1% in Cluster 2 (43.0%) and 43.3% in Cluster 3 (36.4%) (p < 0.001). Treatment discontinuation was observed in 91 individuals (55.2%) out of the total patients. In the multivariate analysis, the presence of cluster 1 was a significant predictor (OR: 7.25, 95% CI: 1.45–36.12). Bayesian dose adjustment was found to significantly reduce the risk of IFX discontinuation (OR: 0.19, 95% CI: 0.46–1.96).

Conclusions

The lack of TDM during induction and a lower proportion of adjustments made through Bayesian methods were associated with a subgroup demonstrating suboptimal pharmacokinetic profiles and reduced drug persistence. These findings highlight the clinical relevance of model-informed TDM in optimizing IFX exposure and minimizing treatment discontinuation in IBD.
背景和目的:炎症性肠病(IBD)具有不同的临床表现和进展,影响IFX暴露。了解IFX血清浓度变化对于特定患者群体的量身定制监测至关重要。本研究的主要目的是分析IBD患者的ITL轨迹,以确定不同的组和亚组,揭示治疗反应的异质性。方法:对西班牙一家地区参考医院接受英夫利昔单抗治疗的IBD患者进行回顾性队列研究。潜伏类线性混合模型用于根据血清英夫利昔单抗随时间的测量来确定亚组。为了分析与IFX停药相关的因素,我们采用了logistic回归和Cox回归模型。结果:本研究纳入165例IBD患者,共分析ITL样本799份。所选择的模型包括三个簇,在线性混合模型中具有随机截距和对时间和自然三次样条时间的随机效应。第1组(20.6%)有较低的IFX暴露,93.9%经历了治疗中断,而第2组(43.0%)和第3组(36.4%)的这一比例分别为45.1%和43.3%。结论:诱导过程中缺乏TDM和通过贝叶斯方法进行调整的比例较低与亚组表现出次优的药代动力学特征和药物持久性降低有关。这些发现强调了模型知情TDM在优化IFX暴露和最小化IBD治疗中断方面的临床相关性。
{"title":"Exploring infliximab serum level variability in inflammatory bowel disease: Comprehensive analysis of patient subgroups and treatment outcomes","authors":"Carles Iniesta-Navalón ,&nbsp;Lorena Rentero-Redondo ,&nbsp;Rosa Gómez-Espín ,&nbsp;Manuel Ríos Saorín ,&nbsp;Isabel Nicolás de Prado ,&nbsp;Juan José Gascón-Cánovas","doi":"10.1016/j.gastrohep.2025.502472","DOIUrl":"10.1016/j.gastrohep.2025.502472","url":null,"abstract":"<div><h3>Background and aims</h3><div>Inflammatory bowel disease (IBD) features diverse clinical presentations and progressions, impacting IFX exposure. Understanding IFX serum concentration changes is crucial for tailored monitoring in specific patient groups. The main objective of this study was to analyze ITL trajectories in patients with IBD to identify distinct groups and subgroups, revealing heterogeneity in treatment responses.</div></div><div><h3>Methods</h3><div>A retrospective cohort study was conducted involving IBD patients treated with infliximab in a regional reference hospital in Spain. Latent class linear mixed models were applied to identify subgroups based on serum infliximab measurements over time. To analyze the factors associated with IFX discontinuation, we employed both logistic regression and Cox regression models.</div></div><div><h3>Results</h3><div>The study included 165 IBD patients, and a total of 799 ITL samples were analyzed. The selected model included three clusters, with a random intercept and a random effect on both time and natural cubic spline time in the linear mixed model. Cluster 1 (20.6%) had lower IFX exposure, with 93.9% experiencing treatment discontinuation, compared to 45.1% in Cluster 2 (43.0%) and 43.3% in Cluster 3 (36.4%) (<em>p</em> <!-->&lt;<!--> <!-->0.001). Treatment discontinuation was observed in 91 individuals (55.2%) out of the total patients. In the multivariate analysis, the presence of cluster 1 was a significant predictor (OR: 7.25, 95% CI: 1.45–36.12). Bayesian dose adjustment was found to significantly reduce the risk of IFX discontinuation (OR: 0.19, 95% CI: 0.46–1.96).</div></div><div><h3>Conclusions</h3><div>The lack of TDM during induction and a lower proportion of adjustments made through Bayesian methods were associated with a subgroup demonstrating suboptimal pharmacokinetic profiles and reduced drug persistence. These findings highlight the clinical relevance of model-informed TDM in optimizing IFX exposure and minimizing treatment discontinuation in IBD.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"48 10","pages":"Article 502472"},"PeriodicalIF":1.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fallo intestinal. Rehabilitación y tratamiento: nociones básicas para gastroenterólogos 肠衰竭。康复与治疗:胃肠病学家的基本概念。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-12-01 Epub Date: 2025-10-21 DOI: 10.1016/j.gastrohep.2025.502603
Cristina Olmedo Moreno , Francisco López Romero-Salazar , María Maíz Jiménez , Carmelo Loinaz Segurola , Yago González Lama
{"title":"Fallo intestinal. Rehabilitación y tratamiento: nociones básicas para gastroenterólogos","authors":"Cristina Olmedo Moreno ,&nbsp;Francisco López Romero-Salazar ,&nbsp;María Maíz Jiménez ,&nbsp;Carmelo Loinaz Segurola ,&nbsp;Yago González Lama","doi":"10.1016/j.gastrohep.2025.502603","DOIUrl":"10.1016/j.gastrohep.2025.502603","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"48 10","pages":"Article 502603"},"PeriodicalIF":1.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145354516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling the hidden risk: Herbal and dietary supplement consumption in liver disease patients 揭示隐藏的风险:肝病患者的草药和膳食补充剂消费。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-12-01 Epub Date: 2025-07-02 DOI: 10.1016/j.gastrohep.2025.502520
Elia Canga , Anna Pocurull , Montserrat Rodriguez-Reyes , Cristina Collazos , Laura Martín , Zoe Mariño , Sabela Lens , Xavier Forns

Introduction

The use of herbal products and dietary supplements (HDS) carries a potential risk of liver toxicity. Data on HDS consumption among patients attending liver disease clinics remain unexplored.

Objective

To determine the frequency, types and reasons for HDS consumption in patients attending a specialized liver disease outpatient clinic.

Methods

Prospective study including consecutive patients attending the hepatology outpatient clinic at the Hospital Clínic of Barcelona from June 2023 to October 2023. Following a standard medical visit, a trained nurse conducted a structured interview to assess HDS consumption.

Results

A total of 150 patients were included, with a median age of 59 (IQR: 49–67) and male predominance (56%, n = 84). Only 12 patients (8%) reported HDS consumption during a standard medical interview, while the number increased to 92 (61%) after nurse-led structured interview. The primary reasons for dietary supplements use included vitamin supplementation (43%), fitness improvement (10.5%) and hair/nail health (10.5%). For herbal products, the most common reason for use was pleasure (73%). Reported HDS products with potential hepatotoxicity (levels A and B) were green tea (n = 16), turmeric with black pepper (n = 11), aloe (n = 2), greater celandine (n = 1) and black cohosh (n = 1).

Conclusion

HDS use is highly prevalent among patients with liver disease, but a structured interview is crucial to detect their consumption, as they usually forget spontaneous reporting. Importantly, a significant proportion of these products carry a risk of hepatic toxicity, underscoring the need for increased patient education and clinical vigilance.
使用草药产品和膳食补充剂(HDS)有潜在的肝毒性风险。在肝病门诊就诊的患者中HDS消费的数据仍未被探索目的:确定在肝病专科门诊就诊的患者中HDS消费的频率、类型和原因。方法:前瞻性研究包括2023年6月至2023年10月在巴塞罗那医院Clínic肝病科门诊就诊的连续患者。在一次标准的医疗访问之后,一名训练有素的护士进行了一次结构化的访谈,以评估HDS的消耗情况。结果:共纳入150例患者,中位年龄59岁(IQR:49 ~ 67),男性居多(56%,n=84)。在标准的医疗访谈中,只有12名患者(8%)报告了HDS的消费,而在护士主导的结构化访谈后,这一数字增加到92名(61%)。使用膳食补充剂的主要原因包括补充维生素(43%)、改善健康(10.5%)和头发/指甲健康(10.5%)。对于草药产品,最常见的使用原因是愉悦(73%)。据报道,具有潜在肝毒性的HDS产品(A级和B级)有绿茶(n=16)、姜黄黑胡椒(n=11)、芦荟(n=2)、白屈菜素(n=1)和黑升麻(n=1)。结论:HDS的使用在肝病患者中非常普遍,但结构化访谈对于检测他们的消费至关重要,因为他们通常会忘记自发报告。重要的是,这些产品中有很大一部分具有肝毒性风险,强调需要加强患者教育和临床警惕。
{"title":"Unveiling the hidden risk: Herbal and dietary supplement consumption in liver disease patients","authors":"Elia Canga ,&nbsp;Anna Pocurull ,&nbsp;Montserrat Rodriguez-Reyes ,&nbsp;Cristina Collazos ,&nbsp;Laura Martín ,&nbsp;Zoe Mariño ,&nbsp;Sabela Lens ,&nbsp;Xavier Forns","doi":"10.1016/j.gastrohep.2025.502520","DOIUrl":"10.1016/j.gastrohep.2025.502520","url":null,"abstract":"<div><h3>Introduction</h3><div>The use of herbal products and dietary supplements (HDS) carries a potential risk of liver toxicity. Data on HDS consumption among patients attending liver disease clinics remain unexplored.</div></div><div><h3>Objective</h3><div>To determine the frequency, types and reasons for HDS consumption in patients attending a specialized liver disease outpatient clinic.</div></div><div><h3>Methods</h3><div>Prospective study including consecutive patients attending the hepatology outpatient clinic at the Hospital Clínic of Barcelona from June 2023 to October 2023. Following a standard medical visit, a trained nurse conducted a structured interview to assess HDS consumption.</div></div><div><h3>Results</h3><div>A total of 150 patients were included, with a median age of 59 (IQR: 49–67) and male predominance (56%, <em>n</em> <!-->=<!--> <!-->84). Only 12 patients (8%) reported HDS consumption during a standard medical interview, while the number increased to 92 (61%) after nurse-led structured interview. The primary reasons for dietary supplements use included vitamin supplementation (43%), fitness improvement (10.5%) and hair/nail health (10.5%). For herbal products, the most common reason for use was pleasure (73%). Reported HDS products with potential hepatotoxicity (levels A and B) were green tea (<em>n</em> <!-->=<!--> <!-->16), turmeric with black pepper (<em>n</em> <!-->=<!--> <!-->11), aloe (<em>n</em> <!-->=<!--> <!-->2), greater celandine (<em>n</em> <!-->=<!--> <!-->1) and black cohosh (<em>n</em> <!-->=<!--> <!-->1).</div></div><div><h3>Conclusion</h3><div>HDS use is highly prevalent among patients with liver disease, but a structured interview is crucial to detect their consumption, as they usually forget spontaneous reporting. Importantly, a significant proportion of these products carry a risk of hepatic toxicity, underscoring the need for increased patient education and clinical vigilance.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"48 10","pages":"Article 502520"},"PeriodicalIF":1.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144564659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fecal elastase-1 and 13C-mixed triglyceride breath test vs. coefficient of fat absorption to diagnose exocrine pancreatic insufficiency after pancreatic surgery 粪便弹性酶-1和13c -混合甘油三酯呼气试验与脂肪吸收系数诊断胰腺手术后外分泌胰功能不全的比较
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-12-01 Epub Date: 2025-05-30 DOI: 10.1016/j.gastrohep.2025.502492
Paula Sirera-Sirera , Núria Lluís , Fèlix Lluís , Pedro Zapater , Pablo López-Guillén , José M. Ramia-Ángel , Rahma Amrani , Trinidad Castillo-García , José Andreu-Viseras , Karina Cárdenas-Jaén , Lucía Guilabert , Sara Pérez-Brotons , Emma Martínez-Moneo , Nerea Gendive-Martin , Iván González Hermoso , Enrique de-Madaria , María José Ferri

Objective

Exocrine pancreatic insufficiency (EPI) is common after pancreatic surgery. In patients with chronic pancreatitis, our previous results supported the use of fecal elastase-1 (FE-1) over the 13C-mixed triglyceride breath test (13C-MTBT) for the diagnosis of EPI. However, it is poorly established how the performance of these two tests compares to the diagnosis of EPI after pancreatic surgery.

Patients and methods

FE-1 and 13C-MTBT were compared with the gold standard coefficient of fat absorption (CFA). Area under ROC curve (AUC) and best cutoffs were used to assess presence of EPI. Patient characteristics were evaluated by extent of pancreatic resection.

Results

The AUC (95% confidence interval) was 0.724 (0.578–0.871) for FE-1 and 0.640 (0.482–0.799) for 13C-MTBT in the diagnosis of EPI. A pairwise comparison of the FE-1 and 13C-MTBT AUCs showed no statistically significant difference (P = .20). The best cut-off point was 65.5 μg/g for FE-1 and 22.5% for 13C-MTBT. According to contingency analysis, both the FE-1 threshold of 65.5 μg/g (P = .005) and the 13C-MTBT threshold of 22.5% (P = .015) showed statistical significance for diagnosing EPI.

Conclusion

FE-1 was more accurate for diagnosing EPI after pancreatic surgery, but the differences were not statistically different.
目的:外分泌性胰腺功能不全(EPI)是胰腺手术后常见的症状。在慢性胰腺炎患者中,我们之前的结果支持使用粪便弹性酶-1 (FE-1)而不是13c -混合甘油三酯呼吸试验(13C-MTBT)来诊断EPI。然而,目前尚不清楚这两项测试的表现如何与胰腺手术后EPI的诊断相比较。患者和方法:将FE-1、13C-MTBT与脂肪吸收金标准系数(CFA)进行比较。ROC曲线下面积(AUC)和最佳截止点(best cutoff)用于评估EPI的存在。通过胰腺切除程度评估患者特征。结果:FE-1诊断EPI的AUC(95%置信区间)为0.724 (0.578 ~ 0.871),13C-MTBT诊断EPI的AUC(95%置信区间)为0.640(0.482 ~ 0.799)。FE-1与13C-MTBT auc两两比较,差异无统计学意义(P= 0.20)。FE-1的最佳截断点为65.5µg/g, 13C-MTBT的最佳截断点为22.5%。经权变分析,FE-1阈值65.5µg/g (P= 0.005)和13C-MTBT阈值22.5% (P= 0.015)对EPI的诊断均有统计学意义。结论:FE-1对胰腺术后EPI的诊断更准确,但差异无统计学意义。
{"title":"Fecal elastase-1 and 13C-mixed triglyceride breath test vs. coefficient of fat absorption to diagnose exocrine pancreatic insufficiency after pancreatic surgery","authors":"Paula Sirera-Sirera ,&nbsp;Núria Lluís ,&nbsp;Fèlix Lluís ,&nbsp;Pedro Zapater ,&nbsp;Pablo López-Guillén ,&nbsp;José M. Ramia-Ángel ,&nbsp;Rahma Amrani ,&nbsp;Trinidad Castillo-García ,&nbsp;José Andreu-Viseras ,&nbsp;Karina Cárdenas-Jaén ,&nbsp;Lucía Guilabert ,&nbsp;Sara Pérez-Brotons ,&nbsp;Emma Martínez-Moneo ,&nbsp;Nerea Gendive-Martin ,&nbsp;Iván González Hermoso ,&nbsp;Enrique de-Madaria ,&nbsp;María José Ferri","doi":"10.1016/j.gastrohep.2025.502492","DOIUrl":"10.1016/j.gastrohep.2025.502492","url":null,"abstract":"<div><h3>Objective</h3><div><span>Exocrine pancreatic insufficiency (EPI) is common after pancreatic surgery. In patients with chronic pancreatitis, our previous results supported the use of fecal elastase-1 (FE-1) over the </span><sup>13</sup>C-mixed triglyceride breath test (<sup>13</sup><span>C-MTBT) for the diagnosis of EPI<span>. However, it is poorly established how the performance of these two tests compares to the diagnosis of EPI after pancreatic surgery.</span></span></div></div><div><h3>Patients and methods</h3><div>FE-1 and <sup>13</sup>C-MTBT were compared with the gold standard coefficient of fat absorption (CFA). Area under ROC curve (AUC) and best cutoffs were used to assess presence of EPI. Patient characteristics were evaluated by extent of pancreatic resection.</div></div><div><h3>Results</h3><div>The AUC (95% confidence interval) was 0.724 (0.578–0.871) for FE-1 and 0.640 (0.482–0.799) for <sup>13</sup>C-MTBT in the diagnosis of EPI. A pairwise comparison of the FE-1 and <sup>13</sup>C-MTBT AUCs showed no statistically significant difference (<em>P</em> <!-->=<!--> <!-->.20). The best cut-off point was 65.5<!--> <!-->μg/g for FE-1 and 22.5% for <sup>13</sup>C-MTBT. According to contingency analysis, both the FE-1 threshold of 65.5<!--> <!-->μg/g (<em>P</em> <!-->=<!--> <!-->.005) and the <sup>13</sup>C-MTBT threshold of 22.5% (<em>P</em> <!-->=<!--> <!-->.015) showed statistical significance for diagnosing EPI.</div></div><div><h3>Conclusion</h3><div>FE-1 was more accurate for diagnosing EPI after pancreatic surgery, but the differences were not statistically different.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"48 10","pages":"Article 502492"},"PeriodicalIF":1.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Análisis de los factores de riesgo de complicación tras la reconstrucción de ileostomía de protección en los pacientes intervenidos por cáncer rectal 直肠癌术后保护性回肠造口重建并发症的危险因素分析。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-12-01 Epub Date: 2025-05-31 DOI: 10.1016/j.gastrohep.2025.502495
Manuel González Bermúdez , María Lourdes García Jiménez , Sergio Rodríguez Rojo , Jose Antonio Romero González , Pablo Concheiro Coello , Javier Aguirrezabalaga González , José Francisco Noguera Aguilar

Objective

To estimate the incidence of complications following ileostomy reversal and to identify associated risk factors.

Patients and methods

A retrospective cohort study was conducted, including patients who underwent rectal cancer surgery with a protective ileostomy. The minimum follow-up period was one year. A univariate analysis was performed to identify potential risk factors for complications, and variables with P<0.1 were included in a multivariate analysis.

Results

Between January 1, 2015, and December 31, 2023, a total of 220 patients underwent surgery. Thirteen percent did not undergo ileostomy reversal. Thus, 193 patients were included in the final analysis. The median time to ileostomy reversal was 292 days. Postoperative complications occurred in approximately 27.5% of cases. Among the potential risk factors, albumin levels < 4 g/dl, open surgical approach for rectal pathology, absence of efferent loop stimulation, and side-to-side anastomosis were associated with P<.1 in univariate analysis. In the multivariate analysis, only low albumin levels and the open surgical approach for rectal pathology remained significantly associated with an increased risk of complications.

Conclusion

Modifiable factors such as the use of a laparoscopic approach for rectal surgery, stimulation of the efferent loop, and optimization of preoperative nutritional status may help reduce the incidence of postoperative complications.
目的:评估回肠造口术逆转术后并发症的发生率,并探讨相关危险因素。患者和方法:进行回顾性队列研究,包括接受直肠癌手术并保护性回肠造口术的患者。最低随访期为一年。进行单因素分析以确定并发症的潜在危险因素,p < 0.1的变量被纳入多因素分析。结果:2015年1月1日至2023年12月31日,共220例患者接受手术治疗。13%的患者没有接受回肠造口术逆转。因此,193例患者被纳入最终分析。回肠造口逆转的中位时间为292天。术后并发症发生率约为27.5%。在潜在的危险因素中,白蛋白水平< 4 g/dL、直肠病理开放手术入路、缺乏传出环刺激和侧对侧吻合在单因素分析中与p < 0.1相关。在多变量分析中,只有低白蛋白水平和直肠病理开放手术入路与并发症风险增加显著相关。结论:采用腹腔镜直肠手术入路、刺激传出袢、优化术前营养状况等可调整因素有助于减少术后并发症的发生。
{"title":"Análisis de los factores de riesgo de complicación tras la reconstrucción de ileostomía de protección en los pacientes intervenidos por cáncer rectal","authors":"Manuel González Bermúdez ,&nbsp;María Lourdes García Jiménez ,&nbsp;Sergio Rodríguez Rojo ,&nbsp;Jose Antonio Romero González ,&nbsp;Pablo Concheiro Coello ,&nbsp;Javier Aguirrezabalaga González ,&nbsp;José Francisco Noguera Aguilar","doi":"10.1016/j.gastrohep.2025.502495","DOIUrl":"10.1016/j.gastrohep.2025.502495","url":null,"abstract":"<div><h3>Objective</h3><div>To estimate the incidence of complications following ileostomy reversal and to identify associated risk factors.</div></div><div><h3>Patients and methods</h3><div>A retrospective cohort study was conducted, including patients who underwent rectal cancer surgery with a protective ileostomy. The minimum follow-up period was one year. A univariate analysis was performed to identify potential risk factors for complications, and variables with <em>P</em>&lt;0.1 were included in a multivariate analysis.</div></div><div><h3>Results</h3><div>Between January 1, 2015, and December 31, 2023, a total of 220 patients underwent surgery. Thirteen percent did not undergo ileostomy reversal. Thus, 193 patients were included in the final analysis. The median time to ileostomy reversal was 292 days. Postoperative complications occurred in approximately 27.5% of cases. Among the potential risk factors, albumin levels &lt;<!--> <!-->4<!--> <!-->g/dl, open surgical approach for rectal pathology, absence of efferent loop stimulation, and side-to-side anastomosis were associated with <em>P</em>&lt;.1 in univariate analysis. In the multivariate analysis, only low albumin levels and the open surgical approach for rectal pathology remained significantly associated with an increased risk of complications.</div></div><div><h3>Conclusion</h3><div>Modifiable factors such as the use of a laparoscopic approach for rectal surgery, stimulation of the efferent loop, and optimization of preoperative nutritional status may help reduce the incidence of postoperative complications.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"48 10","pages":"Article 502495"},"PeriodicalIF":1.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Empleo de ustekinumab como tratamiento de elección en paciente con colitis inmunomediada corticodependiente y secundaria a pembrolizumab Ustekinumab作为免疫介导皮质依赖性结肠炎和继发性Pembrolizumab患者的选择性治疗。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-12-01 Epub Date: 2025-05-21 DOI: 10.1016/j.gastrohep.2025.502469
Alejandro García Martínez, María Regla Gallego Gallegos
{"title":"Empleo de ustekinumab como tratamiento de elección en paciente con colitis inmunomediada corticodependiente y secundaria a pembrolizumab","authors":"Alejandro García Martínez,&nbsp;María Regla Gallego Gallegos","doi":"10.1016/j.gastrohep.2025.502469","DOIUrl":"10.1016/j.gastrohep.2025.502469","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"48 10","pages":"Article 502469"},"PeriodicalIF":1.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spontaneous cholecysto-cutaneous fistula in a patient with peritoneal carcinomatosis 腹膜癌并发自发性胆囊-皮肤瘘1例。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-12-01 Epub Date: 2025-04-12 DOI: 10.1016/j.gastrohep.2025.502447
Miriam Bragado Pascual, Rosanna Villanueva Hernández, M. Pilar Delgado Alvarez, Luis Ricardo Gotuzzo Altez, Juan Manuel Blanco Esteban
{"title":"Spontaneous cholecysto-cutaneous fistula in a patient with peritoneal carcinomatosis","authors":"Miriam Bragado Pascual,&nbsp;Rosanna Villanueva Hernández,&nbsp;M. Pilar Delgado Alvarez,&nbsp;Luis Ricardo Gotuzzo Altez,&nbsp;Juan Manuel Blanco Esteban","doi":"10.1016/j.gastrohep.2025.502447","DOIUrl":"10.1016/j.gastrohep.2025.502447","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"48 10","pages":"Article 502447"},"PeriodicalIF":1.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Documento de posicionamiento de GETECCU sobre fragilidad, edad avanzada y enfermedad inflamatoria intestinal Geteccu关于脆弱性、高龄和炎症性肠病的立场文件。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-12-01 Epub Date: 2025-07-12 DOI: 10.1016/j.gastrohep.2025.502529
Míriam Mañosa , Margalida Calafat , Esther Francia , Francesc Riba , Francisco Mesonero , Cristina Suárez , Santiago García-López , Francisco Losfablos , Xavier Calvet , Eugeni Domènech , Ana Gutiérrez Casbas , Ingrid Ordás , Luis Menchén , Francisco Rodríguez-Moranta , Yamile Zabana
Frailty is a state of vulnerability characterised by a decrease in physiological reserve and the ability to respond to stress, which increases the risk of complications, adverse effects of treatments and functional decline. Assessing frailty allows the biological age of patients to be determined, beyond their chronological age, providing a more accurate picture of their health status and care needs. The proportion of older adults with IBD is increasing in parallel with the ageing of the general population, and it is estimated that in the next decade, more than a third of IBD patients will be over 60 years of age. This population may suffer from complications arising from previously developed IBD and is particularly susceptible to developing side effects from treatment, making comprehensive assessment essential in order to identify those who are most vulnerable. Frailty is compounded by other geriatric syndromes such as comorbidity and polypharmacy, which can significantly interfere with the management and course of IBD, influencing the therapeutic strategy and prognosis.

Objective

In this context, comprehensive geriatric assessment should be systematic in elderly patients with IBD, with the aim of detecting functional deficits and implementing specific interventions for nutritional support, functional rehabilitation and psychological care to optimise their progress. This position paper aims to establish recommendations in this regard based on the available evidence.

Conclusions

The systematic incorporation of comprehensive geriatric assessment in the management of older people with IBD represents an essential strategy for improving clinical outcomes, adapting treatments to the patient's functional capacity and promoting a truly person-centred approach.
虚弱是一种易受伤害的状态,其特征是生理储备和应对压力的能力下降,这增加了并发症、治疗不良反应和功能下降的风险。评估虚弱可以确定患者的生理年龄,而不仅仅是他们的实际年龄,从而更准确地了解他们的健康状况和护理需求。老年IBD患者的比例与普通人群的老龄化同步增加,据估计,在未来十年,超过三分之一的IBD患者将超过60岁。这一人群可能患有先前发展的IBD引起的并发症,并且特别容易因治疗而产生副作用,因此必须进行全面评估,以确定最脆弱的人群。虚弱是由其他老年综合征,如合并症和多药,可以显著干扰IBD的管理和进程,影响治疗策略和预后加重。目的:在此背景下,应对老年IBD患者进行系统的综合老年病学评估,目的是发现功能缺陷,并实施具体的营养支持、功能康复和心理护理干预,以优化其进展。本立场文件旨在根据现有证据提出这方面的建议。结论:在老年IBD患者的管理中,系统地结合全面的老年评估是改善临床结果、使治疗适应患者的功能能力和促进真正以人为本的方法的重要策略。
{"title":"Documento de posicionamiento de GETECCU sobre fragilidad, edad avanzada y enfermedad inflamatoria intestinal","authors":"Míriam Mañosa ,&nbsp;Margalida Calafat ,&nbsp;Esther Francia ,&nbsp;Francesc Riba ,&nbsp;Francisco Mesonero ,&nbsp;Cristina Suárez ,&nbsp;Santiago García-López ,&nbsp;Francisco Losfablos ,&nbsp;Xavier Calvet ,&nbsp;Eugeni Domènech ,&nbsp;Ana Gutiérrez Casbas ,&nbsp;Ingrid Ordás ,&nbsp;Luis Menchén ,&nbsp;Francisco Rodríguez-Moranta ,&nbsp;Yamile Zabana","doi":"10.1016/j.gastrohep.2025.502529","DOIUrl":"10.1016/j.gastrohep.2025.502529","url":null,"abstract":"<div><div>Frailty is a state of vulnerability characterised by a decrease in physiological reserve and the ability to respond to stress, which increases the risk of complications, adverse effects of treatments and functional decline. Assessing frailty allows the biological age of patients to be determined, beyond their chronological age, providing a more accurate picture of their health status and care needs. The proportion of older adults with IBD is increasing in parallel with the ageing of the general population, and it is estimated that in the next decade, more than a third of IBD patients will be over 60 years of age. This population may suffer from complications arising from previously developed IBD and is particularly susceptible to developing side effects from treatment, making comprehensive assessment essential in order to identify those who are most vulnerable. Frailty is compounded by other geriatric syndromes such as comorbidity and polypharmacy, which can significantly interfere with the management and course of IBD, influencing the therapeutic strategy and prognosis.</div></div><div><h3>Objective</h3><div>In this context, comprehensive geriatric assessment should be systematic in elderly patients with IBD, with the aim of detecting functional deficits and implementing specific interventions for nutritional support, functional rehabilitation and psychological care to optimise their progress. This position paper aims to establish recommendations in this regard based on the available evidence.</div></div><div><h3>Conclusions</h3><div>The systematic incorporation of comprehensive geriatric assessment in the management of older people with IBD represents an essential strategy for improving clinical outcomes, adapting treatments to the patient's functional capacity and promoting a truly person-centred approach.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"48 10","pages":"Article 502529"},"PeriodicalIF":1.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Valor pronóstico del índice de Lille precoz en los pacientes con hepatitis asociada al alcohol grave 早期里尔评分对重度酒精相关性肝炎患者的预后价值。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-12-01 Epub Date: 2025-06-20 DOI: 10.1016/j.gastrohep.2025.502517
Ana Suárez-Saro Fernández , Mónica Barreales Valbuena , Cristina Martín-Arriscado Arroba , Elena Gómez Domínguez , Álvaro Hidalgo Romero , Inmaculada Fernández Vázquez

Objective

To evaluate the effectiveness of the Lille Index (LI) on day 2 (LI2) and day 4 (LI4) in predicting short-term mortality in patients with severe alcohol-associated hepatitis (SAH) and to assess its concordance compared to the Lille Index on day 7 (LI7).

Patients and methods

This retrospective, observational, single-center study included SAH patients admitted between 2016 and 2023. SAH was defined as a Maddrey score ≥32 and/or a MELD score ≥21. The predictive ability of LI2, LI4, and LI7 for 28-, 90-, and 180-day mortality was analyzed using AUC, Cox regression (Hazar Ratio (HR)), and Kaplan-Meier curves.

Results

Among 65 SAH patients, 62 received corticosteroids. Median follow-up was 722 days. LI2 was associated with a 28-day mortality HR of 33.1 (95% CI: 3.8-287.3), similar to LI7 (HR: 13.2; 95% CI: 2.2-81.2). AUCs for 28-day mortality were 0.818 for LI2, 0.794 for LI4, and 0.809 for LI7 (P>.05). The proportion of patients classified by prognosis was similar for LI2 vs. LI7 (68.33% vs. 70.97%, P=.752) and LI4 vs. LI7 (73.33% vs. 70.97%, P=.771). Concordance between LI2 and LI7 was 85%, and between LI4 and LI7 was 93.33%.

Results

Among 65 SAH patients, 62 received corticosteroids. The median follow-up was 722 days. LI2 was associated with a 28-day mortality HR of 33.1 (95% CI: 3.8-287.3), similar to LI7 (HR: 13.2; 95% CI: 2.2-81.2). AUCs for 28-day mortality were 0.818 for LI2, 0.794 for LI4, and 0.809 for LI7 (P>.05). The proportion of patients classified by prognosis was similar for LI2 vs. LI7 (P=.752) and LI4 vs. LI7 (P=.771). Concordance between LI2 and LI7 was 85%, and between LI4 and LI7, 93.33%.

Conclusions

LI2 and LI4 were comparable to LI7 in predicting short-term mortality in SAH. Earlier calculation, particularly LI2, could anticipate clinical decisions in poor prognosis patients, such as corticosteroid discontinuation or evaluation for liver transplantation in selected cases.
目的:评价Lille指数(LI)第2天(LI2)和第4天(LI4)预测严重酒精相关性肝炎(SAH)患者短期死亡率的有效性,并与Lille指数第7天(LI7)比较其一致性。患者和方法:这项回顾性、观察性、单中心研究纳入了2016年至2023年住院的SAH患者。SAH定义为Maddrey评分≥32和/或MELD评分≥21。采用AUC、Cox回归(Hazar Ratio, HR)和Kaplan-Meier曲线分析LI2、LI4和LI7对28、90和180天死亡率的预测能力。结果:65例SAH患者中,62例接受糖皮质激素治疗。中位随访时间为722天。LI2与28天死亡率相关,HR为33.1 (95% CI: 3.8-287.3),与LI7相似(HR: 13.2;95% ci: 2.2-81.2)。LI2的28天死亡率auc为0.818,LI4为0.794,LI7为0.809 (p < 0.05)。LI2与LI7按预后分类的患者比例相似(68.33% vs. 70.97%, p=0.752), LI4与LI7按预后分类的患者比例相似(73.33% vs. 70.97%, p=0.771)。LI2与LI7的一致性为85%,LI4与LI7的一致性为93.33%。结果:65例SAH患者中,62例接受糖皮质激素治疗。中位随访时间为722天。LI2与28天死亡率相关,HR为33.1 (95% CI: 3.8-287.3),与LI7相似(HR: 13.2;95% ci: 2.2-81.2)。LI2的28天死亡率auc为0.818,LI4为0.794,LI7为0.809 (p < 0.05)。LI2与LI7、LI4与LI7按预后分类的患者比例相似(p=0.752)。LI2与LI7的一致性为85%,LI4与LI7的一致性为93.33%。结论:LI2和LI4在预测SAH短期死亡率方面与LI7相当。早期计算,特别是LI2,可以预测预后不良患者的临床决策,例如在选定的病例中停用皮质类固醇或评估肝移植。
{"title":"Valor pronóstico del índice de Lille precoz en los pacientes con hepatitis asociada al alcohol grave","authors":"Ana Suárez-Saro Fernández ,&nbsp;Mónica Barreales Valbuena ,&nbsp;Cristina Martín-Arriscado Arroba ,&nbsp;Elena Gómez Domínguez ,&nbsp;Álvaro Hidalgo Romero ,&nbsp;Inmaculada Fernández Vázquez","doi":"10.1016/j.gastrohep.2025.502517","DOIUrl":"10.1016/j.gastrohep.2025.502517","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the effectiveness of the Lille Index (LI) on day 2 (LI2) and day 4 (LI4) in predicting short-term mortality in patients with severe alcohol-associated hepatitis (SAH) and to assess its concordance compared to the Lille Index on day 7 (LI7).</div></div><div><h3>Patients and methods</h3><div>This retrospective, observational, single-center study included SAH patients admitted between 2016 and 2023. SAH was defined as a Maddrey score ≥32 and/or a MELD score ≥21. The predictive ability of LI2, LI4, and LI7 for 28-, 90-, and 180-day mortality was analyzed using AUC, Cox regression (Hazar Ratio (HR)), and Kaplan-Meier curves.</div></div><div><h3>Results</h3><div>Among 65 SAH patients, 62 received corticosteroids. Median follow-up was 722 days. LI2 was associated with a 28-day mortality HR of 33.1 (95% <span>C</span>I: 3.8-287.3), similar to LI7 (HR: 13.2; 95% CI: 2.2-81.2). AUCs for 28-day mortality were 0.818 for LI2, 0.794 for LI4, and 0.809 for LI7 (<em>P</em>&gt;.05). The proportion of patients classified by prognosis was similar for LI2 vs. LI7 (68.33% vs. 70.97%, <em>P</em>=.752) and LI4 vs. LI7 (73.33% vs. 70.97%, <em>P</em>=.771). Concordance between LI2 and LI7 was 85%, and between LI4 and LI7 was 93.33%.</div></div><div><h3>Results</h3><div>Among 65 SAH patients, 62 received corticosteroids. The median follow-up was 722 days. LI2 was associated with a 28-day mortality HR of 33.1 (95% CI: 3.8-287.3), similar to LI7 (HR: 13.2; 95% CI: 2.2-81.2). AUCs for 28-day mortality were 0.818 for LI2, 0.794 for LI4, and 0.809 for LI7 (<em>P</em>&gt;.05). The proportion of patients classified by prognosis was similar for LI2 vs. LI7 (<em>P</em>=.752) and LI4 vs. LI7 (<em>P</em>=.771). Concordance between LI2 and LI7 was 85%, and between LI4 and LI7, 93.33%.</div></div><div><h3>Conclusions</h3><div>LI2 and LI4 were comparable to LI7 in predicting short-term mortality in SAH. Earlier calculation, particularly LI2, could anticipate clinical decisions in poor prognosis patients, such as corticosteroid discontinuation or evaluation for liver transplantation in selected cases.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"48 10","pages":"Article 502517"},"PeriodicalIF":1.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144368789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insights into the status of the quality of nursing care in patients with inflammatory bowel disease: A nationwide survey (The MAPEA Project) 炎性肠病患者护理质量现状的洞察:一项全国性调查(the MAPEA Project)。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-12-01 Epub Date: 2025-05-14 DOI: 10.1016/j.gastrohep.2025.502464
Ester Navarro-Correal , Diana Muñoz-Gómez , Adriana Rivera-Sequeiros , Francisca Murciano-Gonzalo , on behalf of the MAPEA Research Group

Background and aims

This study aimed to provide a comprehensive nationwide assessment of the status of nursing management in inflammatory bowel disease (IBD).

Methods

A nationwide observational cross-sectional survey study was conducted. Nurses involved in the care of patients with IBD completed the 90-item Nursing Care Quality in IBD Assessment (NCQ-IBD) questionnaire which classifies the level of quality of care from A (highest) to D (lowest).

Results

A total of 71 f questionnaires were analyzed. In this study, category A was achieved in 2 (2.8%) cases, category B in 53 (74.6%), and category C in 16 (22.5%). Of the list of 27 professional competencies identified for a specialized IBD nurse, 23 (85.2%) were met by more than 70% of participants. Regarding the presence of specific nursing IBD care only 28 (39.4%) worked for more than 4.5 days/week. About 88.7% of nurses used clinical practice guidelines or protocols and 74.6% applied scales for assessing anxiety and depression, but just 18.8% and 25.4% evaluated IBD classification and activity indexes, respectively. Only 53.5% of participants reported to have available training plan in IBD. In the last 5 years, 25.4% of professionals had participated in more than five research projects, 9.9% had presented more than five communications in meetings, and 14.1% had published more than three articles.

Conclusions

Nursing care was highly satisfactory. Signage on nursing consultation doors, administrative support, holiday coverage, encouraging research, and primarily increasing the ratio of nurses working full-time, are areas for improvement.
背景和目的:本研究旨在全面评估全国范围内炎症性肠病(IBD)护理管理状况。方法:在全国范围内进行观察性横断面调查研究。参与IBD患者护理的护士完成了90项IBD护理质量评估(NCQ-IBD)问卷,该问卷将护理质量水平从A(最高)到D(最低)进行分类。结果:共分析问卷71份。本研究中,A类2例(2.8%),B类53例(74.6%),C类16例(22.5%)。在为IBD专业护士确定的27项专业能力清单中,超过70%的参与者满足了23项(85.2%)。关于IBD护理的特殊护理,只有28人(39.4%)每周工作超过4.5天。约88.7%的护士使用临床实践指南或方案,74.6%的护士使用量表评估焦虑和抑郁,但分别只有18.8%和25.4%的护士评估IBD分类和活动指标。只有53.5%的参与者报告有IBD培训计划。在过去5年中,25.4%的专业人员参与了5个以上的研究项目,9.9%的专业人员在会议上发表了5次以上的交流,14.1%的专业人员发表了3篇以上的文章。结论:护理效果满意。护理咨询门上的标识、行政支持、假期覆盖、鼓励研究,主要是提高全职护士的比例,这些都是需要改进的地方。
{"title":"Insights into the status of the quality of nursing care in patients with inflammatory bowel disease: A nationwide survey (The MAPEA Project)","authors":"Ester Navarro-Correal ,&nbsp;Diana Muñoz-Gómez ,&nbsp;Adriana Rivera-Sequeiros ,&nbsp;Francisca Murciano-Gonzalo ,&nbsp;on behalf of the MAPEA Research Group","doi":"10.1016/j.gastrohep.2025.502464","DOIUrl":"10.1016/j.gastrohep.2025.502464","url":null,"abstract":"<div><h3>Background and aims</h3><div>This study aimed to provide a comprehensive nationwide assessment of the status of nursing management in inflammatory bowel disease (IBD).</div></div><div><h3>Methods</h3><div>A nationwide observational cross-sectional survey study was conducted. Nurses involved in the care of patients with IBD completed the 90-item Nursing Care Quality in IBD Assessment (NCQ-IBD) questionnaire which classifies the level of quality of care from A (highest) to D (lowest).</div></div><div><h3>Results</h3><div>A total of 71 f questionnaires were analyzed. In this study, category A was achieved in 2 (2.8%) cases, category B in 53 (74.6%), and category C in 16 (22.5%). Of the list of 27 professional competencies identified for a specialized IBD nurse, 23 (85.2%) were met by more than 70% of participants. Regarding the presence of specific nursing IBD care only 28 (39.4%) worked for more than 4.5<!--> <!-->days/week. About 88.7% of nurses used clinical practice guidelines or protocols and 74.6% applied scales for assessing anxiety and depression, but just 18.8% and 25.4% evaluated IBD classification and activity indexes, respectively. Only 53.5% of participants reported to have available training plan in IBD. In the last 5 years, 25.4% of professionals had participated in more than five research projects, 9.9% had presented more than five communications in meetings, and 14.1% had published more than three articles.</div></div><div><h3>Conclusions</h3><div>Nursing care was highly satisfactory. Signage on nursing consultation doors, administrative support, holiday coverage, encouraging research, and primarily increasing the ratio of nurses working full-time, are areas for improvement.</div></div>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"48 10","pages":"Article 502464"},"PeriodicalIF":1.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Gastroenterologia y hepatologia
全部 Geobiology Geosci. J. Acta Geophys. Ocean and Coastal Research ACTA GEOL POL B SOC GEOL MEX GEOL BELG GROUNDWATER Aust. J. Earth Sci. Environ. Eng. Manage. J. J. Geog. Sci. Prog. Oceanogr. QUATERNAIRE Int. J. Biometeorol. ECOLOGY IDOJARAS ITAL J REMOTE SENS Geochem. Int. Vadose Zone J. Environmental dermatology : the official journal of the Japanese Society for Contact Dermatitis Polar Sci. Environ. Eng. Sci. Russ. Meteorol. Hydrol. PALAEOGEOGR PALAEOCL Appl. Clay Sci. N. Z. J. Geol. Geophys. J. Mar. Syst. Earth Syst. Dyn. Geochem. J. INDIAN J GEO-MAR SCI Études Caribéennes ARCH ACOUST Environ. Toxicol. Pharmacol. IEEE Trans. Appl. Supercond. Curr. Appl Phys. npj Clim. Atmos. Sci. Big Earth Data Newsl. Stratigr. ACTA ORTHOP TRAUMATO ENVIRON ENG GEOSCI Bull. Geol. Soc. Den. Nat. Hazards Earth Syst. Sci. Round Table ENVIRON HEALTH-GLOB 2011 Annual Report Conference on Electrical Insulation and Dielectric Phenomena EPISODES ACTA CARSOLOGICA Paleontol. Res. Adv. Meteorol. Geochim. Cosmochim. Acta ACTA GEOL SIN-ENGL Acta Oceanolog. Sin. BIOGEOSCIENCES J. Meteorolog. Res. Archaeol. Anthropol. Sci. Hydrol. Earth Syst. Sci. Carbon Balance Manage. ACTA PHARMACEUT Basin Res. GEOLOGY Ecol. Monogr. Am. Mineral. Q. J. Eng. Geol. Hydrogeol. Geostand. Geoanal. Res. ARCT ANTARCT ALP RES J. Clim. Acta Geochimica Adv. Atmos. Sci. Revista Chilena de Obstetricia y Ginecologia J. Atmos. Chem. AAPG Bull. Int. Geol. Rev. Environ. Technol. Innovation Am. J. Phys. Anthropol. ARCHAEOMETRY Int. J. Disaster Risk Reduct. J. Hydrol. [Hokkaido igaku zasshi] The Hokkaido journal of medical science Atmos. Meas. Tech. Annu. Rev. Earth Planet. Sci. 2011 IEEE 2nd International Conference on Computing, Control and Industrial Engineering Am. J. Sci. ACTA PETROL SIN Atmos. Chem. Phys. Appl. Geochem. Ann. Glaciol. Atmos. Res. Hydrol. Processes IZV-PHYS SOLID EART+ Geochem. Trans. Aquat. Geochem. Int. J. Geomech. Biomedicine (India) Int. J. Geog. Inf. Sci. Int. J. Climatol. Org. Geochem. Geodezia es Kartografia Nat. Geosci. REV BRAS PALEONTOLOG J. Atmos. Oceanic Technol.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1